Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00095147 · ClinicalTrials.gov registry record · Phase 3
Abatacept and Infliximab in Combination With Methotrexate in Subjects With Rheumatoid Arthritis
A Phase 3 study, sponsored by Bristol-Myers Squibb.
- Completed
- Registry status
- Phase 3
- Development phase
- 431
- Enrollment target
NCT00095147 is a Phase 3 study that has completed, run by Bristol-Myers Squibb. The registered enrollment target is 431 participants.
The verdict
NCT00095147, a Phase 3 study, has completed, sponsored by Bristol-Myers Squibb.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 431 participants
- Enrollment target
Study Summary
The purpose of this clinical research study is to learn if Abatacept or Infliximab in combination with Methotrexate demonstrate a greater reduction in disease activity over placebo.
Interventions
- DRUG Abatacept (ABA) + Methotrexate (MTX), double-blind (DB)
- DRUG Infliximab (INF) + MTX, DB
- DRUG Placebo (PLA) + MTX, DB
- DRUG PLA + MTX switched to ABA+ MTX, DB
- DRUG ABA, open-label (OL)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 431 participants |
| Start Date | 2005-02 |
| Est. Completion | 2009-07 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00095147
The ClinicalTrials.gov registry entry for NCT00095147 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 431 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Bristol-Myers Squibb, which has 1,025 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 5 interventions - of which Abatacept (ABA) + Methotrexate (MTX), double-blind (DB) is the first listed.
NCT00095147 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00095147 about?
NCT00095147 is a clinical study titled "Abatacept and Infliximab in Combination With Methotrexate in Subjects With Rheumatoid Arthritis". The purpose of this clinical research study is to learn if Abatacept or Infliximab in combination with Methotrexate demonstrate a greater reduction in disease activity over placebo.
What is the current status of trial NCT00095147?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 431 participants. The study started on 2005-02. Estimated completion is 2009-07.
What interventions are being tested in trial NCT00095147?
The interventions under investigation include: Abatacept (ABA) + Methotrexate (MTX), double-blind (DB) (DRUG), Infliximab (INF) + MTX, DB (DRUG), Placebo (PLA) + MTX, DB (DRUG), PLA + MTX switched to ABA+ MTX, DB (DRUG), ABA, open-label (OL) (DRUG).
Who is sponsoring clinical trial NCT00095147?
This trial is sponsored by Bristol-Myers Squibb, which has 1,025 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.